Skip to main content
letter
. 2018 Nov 26;8(12):124. doi: 10.1038/s41408-018-0161-9

Table 1.

Baseline characteristics and thrombosis during follow-up in 1:2 propensity-score-matched patients with Polycythemia Vera treated with phlebotomy only or hydroxyurea

1:2 random-samplea matched cohort (n = 951)
PHL (n = 317) HU (n = 634) p
Baseline characteristics
 Age at enrolment ≥ 60, n (%) 172 (54.3%) 346 (54.6%) 0.272
 Male, n (%) 221 (69.7%) 463 (73.0%) 0.195
 Years from diagnosis of PV to enrolment ≥ 5, n (%) 92 (29.0%) 161 (25.4%) 0.148
 Prior thrombosis, n (%) 104 (32.8%) 221 (34.9%) 0.915
 High risk, n (%) 202 (63.7%) 421 (66.4%) 0.127
 Active smoking, n (%) 65 (20.5%) 95 (15.0%) 0.901
 Hypertension, n (%) 131 (41.3%) 229 (36.1%) 0.841
 Diabetes mellitus, n (%) 25 (7.9%) 41 (6.5%) 0.482
 Aspirin use, n (%) 177 (55.8%) 359 (56.6%) 0.393
 Oral anticoagulant, n (%) 19 (6.0%) 36 (5.7%) 0.057
 BMI categories, n (%)
 Underweight /normal range 142 (44.8%) 279 (44.0%) 0.670
 Overweight 139 (43.8%) 293 (46.2%)
 Obese 36 (11.4%) 62 (9.8%)
Follow-up
 Median total follow-up (IQR), months 29.9 (15.1, 41.0) 34.7 (24.1, 45.3) 0.001
 Median treatment duration (IQR), months 25.8 (12.7, 37.3) 24.0 (12.0, 36.0) 0.696
Arterial thrombosis 20 (6.3%) 15 (2.4%) 0.002
 IR/100 PY (95% CI) 2.62 (1.69, 4.05) 0.84 (0.51, 1.39) 0.001
 Myocardial infarction 1 5
 Stroke 8 2
 Transient ischemic attack 7 8
 Peripheral arterial thrombosis 4 0
Venous thrombosis 10 (3.2%) 16 (2.5%) 0.574
 IR/100 PY (95% CI) 1.29 (0.69, 2.40) 0.90 (0.55, 1.47) 0.380
 Deep vein thrombosis 4 9
 Superficial vein thrombosis 6 7

PHL Phlebotomy, HU hydroxyurea, IQR interquartile range, IR incidence rate, PY person-years

aTwo randomly sampled HU patients: 1 PHL patient in each matched subset. Matching was done using the nearest neighbor method with replacement and with caliper of width equal to 0.2 of the pooled standard deviation of the logit of PS